REGENXBIO Inc.
RGNX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 39.2% | -76% | 319.6% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -107.9% | 57.3% | 96.1% | 70.2% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -151% | -262.1% | 20.9% | -177.9% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -208.3% | -331.8% | 6.8% | -241.3% |
| EPS Diluted | -1.2 | -1.38 | 0.12 | -1.01 |
| % Growth | 13% | -1,250% | 111.9% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |